IHH reported FY2025 revenue of RM25.7 billion, up 6%, with EBITDA of RM5.6 billion, up 3%. Profit attributable to shareholders fell 21% to RM2.1 billion, which the group said was due to unrealised losses from currency translation. For Q4 2025, revenue slipped 2% to RM6.6 billion and profit attributable to shareholders declined 28% to RM528 million, which IHH attributed largely to “paper losses” from a stronger ringgit. Profit attributable to shareholders excluding exceptional items rose 62% to RM513 million. The board approved a FY2025 dividend of 10.5 sen per share. IHH reported net debt-to-EBITDA of 2.4x as at 31 December 2025 and said it is targeting double-digit ROE by 2028. Operationally, it highlighted continued growth in Malaysia’s medical tourism and day cases model, integration benefits in India between Fortis and Gleneagles India, resilience in Singapore with Mount Elizabeth Orchard expected to stabilise in H2 2026, and Gleneagles Hong Kong reaching profit attributable to shareholders breakeven in December 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IHH Healthcare Berhad published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: 47I8CS58KN9XQREQ) on February 27, 2026, and is solely responsible for the information contained therein.